MX2023001071A - Tratamiento de la migraña. - Google Patents
Tratamiento de la migraña.Info
- Publication number
- MX2023001071A MX2023001071A MX2023001071A MX2023001071A MX2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A MX 2023001071 A MX2023001071 A MX 2023001071A
- Authority
- MX
- Mexico
- Prior art keywords
- migraine
- treatment
- atogepant
- administration
- present disclosure
- Prior art date
Links
- 208000019695 Migraine disease Diseases 0.000 title abstract 2
- 206010027599 migraine Diseases 0.000 title abstract 2
- QIVUCLWGARAQIO-OLIXTKCUSA-N (3s)-n-[(3s,5s,6r)-6-methyl-2-oxo-1-(2,2,2-trifluoroethyl)-5-(2,3,6-trifluorophenyl)piperidin-3-yl]-2-oxospiro[1h-pyrrolo[2,3-b]pyridine-3,6'-5,7-dihydrocyclopenta[b]pyridine]-3'-carboxamide Chemical compound C1([C@H]2[C@H](N(C(=O)[C@@H](NC(=O)C=3C=C4C[C@]5(CC4=NC=3)C3=CC=CN=C3NC5=O)C2)CC(F)(F)F)C)=C(F)C=CC(F)=C1F QIVUCLWGARAQIO-OLIXTKCUSA-N 0.000 abstract 1
- 229940070146 atogepant Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
- Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063103353P | 2020-07-29 | 2020-07-29 | |
| US202063070449P | 2020-08-26 | 2020-08-26 | |
| US202063087175P | 2020-10-02 | 2020-10-02 | |
| US202063092211P | 2020-10-15 | 2020-10-15 | |
| US202063129362P | 2020-12-22 | 2020-12-22 | |
| US202163201254P | 2021-04-20 | 2021-04-20 | |
| PCT/US2021/043791 WO2022026767A1 (en) | 2020-07-29 | 2021-07-29 | Treatment of migraine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023001071A true MX2023001071A (es) | 2023-05-12 |
Family
ID=80003948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023001071A MX2023001071A (es) | 2020-07-29 | 2021-07-29 | Tratamiento de la migraña. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12090148B2 (enExample) |
| EP (1) | EP4188375A4 (enExample) |
| JP (1) | JP2023535744A (enExample) |
| CN (1) | CN116390712A (enExample) |
| AU (1) | AU2021319090A1 (enExample) |
| BR (1) | BR112023001615A2 (enExample) |
| CA (1) | CA3190176A1 (enExample) |
| MX (1) | MX2023001071A (enExample) |
| WO (1) | WO2022026767A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| US12168004B2 (en) | 2014-02-05 | 2024-12-17 | Merck Sharp & Dohme Llc | Treatment of migraine |
| US12383545B1 (en) | 2018-06-08 | 2025-08-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
| WO2023055758A1 (en) * | 2021-09-29 | 2023-04-06 | Pfizer Ireland Pharmaceuticals | Preventative treatment of migraine |
| AU2023231645A1 (en) * | 2022-03-09 | 2024-09-12 | Allergan Pharmaceuticals International Limited | Preventive treatment of migraine |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| US6103260A (en) | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
| US20040076668A1 (en) | 2002-07-03 | 2004-04-22 | Pfizer Inc. | Controlled-release pharmaceutical formulations |
| AU2004222378B2 (en) | 2003-03-14 | 2008-08-14 | Merck Sharp & Dohme Corp. | Carboxamide spirohydantoin CGRP receptor antagonists |
| US7205293B2 (en) | 2003-03-14 | 2007-04-17 | Merck & Co., Inc. | Benodiazepine spirohydantoin CGRP receptor antagonists |
| JO2355B1 (en) | 2003-04-15 | 2006-12-12 | ميرك شارب اند دوم كوربوريشن | Hereditary calcitonin polypeptide receptor antagonists |
| CA2543458A1 (en) | 2003-10-24 | 2005-05-12 | Josef Rettenmaier & Soehne Gmbh & Co., Kg | Process for co-spray drying agents with dry silicified mcc |
| ATE464305T1 (de) | 2004-09-13 | 2010-04-15 | Merck Sharp & Dohme | Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors |
| US7390798B2 (en) | 2004-09-13 | 2008-06-24 | Merck & Co., Inc. | Carboxamide spirolactam CGRP receptor antagonists |
| DE102004063755A1 (de) | 2004-12-29 | 2006-07-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von CGRP-Antagonisten zur Behandlung und Vorbeugung von Hitzewallungen bei Patienten mit Prostatakrebs |
| CA2599925A1 (en) | 2005-03-14 | 2006-09-21 | Merck & Co., Inc. | Cgrp receptor antagonists |
| AU2007212197B2 (en) | 2006-02-09 | 2012-12-13 | Merck Sharp & Dohme Corp. | Polymer formulations of CETP inhibitors |
| BRPI0711352A2 (pt) | 2006-05-09 | 2011-09-27 | Merck & Co Inc | composto, composição farmacêutica, e, métodos para o antagonismo de atividade receptora de cgrp em um mamìfero, e para, tratar, controlar, melhorar ou reduzir o risco de dor de cabeça, enxaqueca , ou cefaléia vascular |
| EP2161996B1 (en) | 2007-06-05 | 2014-07-16 | Merck Sharp & Dohme Corp. | Heterocyclic carboxamide cgrp receptor antagonists |
| US8450327B2 (en) | 2007-10-18 | 2013-05-28 | Boehringer Ingelheim International Gmbh | CGRP antagonists |
| WO2009065922A2 (de) | 2007-11-22 | 2009-05-28 | Boehringer Ingelheim International Gmbh | Organische verbindungen |
| WO2009100090A1 (en) | 2008-02-05 | 2009-08-13 | Merck & Co., Inc. | Prodrugs of cgrp receptor antagonist |
| US8044043B2 (en) | 2008-04-11 | 2011-10-25 | Bristol-Myers Squibb Company | CGRP receptor antagonists |
| US20150023888A1 (en) | 2008-09-05 | 2015-01-22 | Map Pharmaceuticals, Inc. | Method of Using Dihydroergotamine for Pre-emptive Treatment of Migraine |
| DK3222277T3 (da) | 2009-03-31 | 2020-05-11 | Ligand Pharm Inc | Biphenylsulfonamidendothelin- og angiotensin II-receptorantagonist til behandling af glomerulosklerose og IgA-induceret nefropati |
| US8765763B2 (en) | 2009-06-05 | 2014-07-01 | Boehringer Ingelheim International Gmbh | Substituted piperazines as CGRP antagonists |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| UA113500C2 (xx) | 2010-10-29 | 2017-02-10 | Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб | |
| TWI522355B (zh) | 2010-11-12 | 2016-02-21 | 默沙東藥廠 | 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑 |
| WO2012064911A1 (en) | 2010-11-12 | 2012-05-18 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide indane cgrp receptor antagonists |
| WO2012087777A1 (en) | 2010-12-22 | 2012-06-28 | Merck Sharp & Dohme Corp. | Fused heterocyclic indane carboxamide cgrp receptor antagonists |
| US9067941B2 (en) | 2010-12-22 | 2015-06-30 | Merck Sharp & Dohme Corp. | Fused heterocyclic azaindane carboxamide CGRP receptor antagonists |
| EP2654726A1 (en) | 2011-03-08 | 2013-10-30 | Zalicus Pharmaceuticals Ltd. | Solid dispersion formulations and methods of use thereof |
| EP2685826B1 (en) | 2011-03-18 | 2016-02-03 | Merck Sharp & Dohme Corp. | Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| US9109209B2 (en) | 2011-09-08 | 2015-08-18 | Codexis, Inc. | Biocatalysts and methods for the synthesis of substituted lactams |
| AU2013232191B2 (en) | 2012-03-14 | 2017-03-30 | Merck Sharp & Dohme Llc | Bis-quarternary cinchona alkaloid salts as asymmetric phase transfer catalysts |
| US9487523B2 (en) | 2012-03-14 | 2016-11-08 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| CN104411295B (zh) | 2012-04-25 | 2017-10-10 | 伊诺威斯药物公司 | 敏感化组合物和使用方法 |
| US9174989B2 (en) | 2012-05-09 | 2015-11-03 | Merck Sharp & Dohme Corp. | Process for making CGRP receptor antagonists |
| EP2846799B1 (en) | 2012-05-09 | 2017-11-15 | Merck Sharp & Dohme Corp. | Spirolactam cgrp receptor antagonists |
| US9227973B2 (en) | 2012-05-09 | 2016-01-05 | Merck Sharp & Dohme Corp. | Pyridine CGRP receptor antagonists |
| WO2013169574A2 (en) | 2012-05-09 | 2013-11-14 | Merck Sharp & Dohme Corp. | Aliphatic spirolactam cgrp receptor antagonists |
| NZ747040A (en) | 2013-03-15 | 2020-02-28 | Tonix Pharmaceuticals Inc | Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride |
| RU2690006C2 (ru) | 2013-09-16 | 2019-05-30 | Мерк Шарп И Доум Корп. | Композиции антагонистов рецепторов cgrp |
| EP3102564A4 (en) | 2014-02-05 | 2017-10-18 | Merck Sharp & Dohme Corp. | Tablet formulation for cgrp-active compounds |
| US20160346198A1 (en) | 2014-02-05 | 2016-12-01 | Merck Sharp & Dohme Corp. | Novel disintegration systems for pharmaceutical dosage forms |
| EP3110427A4 (en) | 2014-02-24 | 2018-05-30 | Urigen Pharmaceuticals, Inc. | Compositions of pentosan polysulfate salts for oral administration and methods of use |
| AU2015305696B2 (en) | 2014-08-22 | 2019-08-29 | Pharma& Schweiz Gmbh | High dosage strength tablets of rucaparib |
| JP6673924B2 (ja) | 2015-01-23 | 2020-03-25 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 肝機能障害および／または腎機能障害を有する対象における疼痛を治療するためのセブラノパドール |
| EA201890578A1 (ru) | 2015-09-24 | 2018-12-28 | Тева Фармасьютикалз Интернэшнл Гмбх | Предотвращение, лечение и снижение (персистирующей) посттравматической головной боли |
| US20180092899A1 (en) | 2016-09-30 | 2018-04-05 | Merck Sharp & Dohme Corp. | Method of treating acute migraine with cgrp-active compound |
| CN110621343A (zh) | 2017-03-02 | 2019-12-27 | 贝丝以色列女执事医疗中心 | 选择对针对降钙素基因相关肽的抗体有反应的头痛患者 |
| TWI754772B (zh) | 2017-09-06 | 2022-02-11 | 美商美國禮來大藥廠 | 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法 |
| US20190135927A1 (en) | 2017-09-29 | 2019-05-09 | Bhl Patent Holdings, Llc | Migraine, headache, chronic pain treatment, and prophylaxis options |
| AU2018362018A1 (en) * | 2017-11-06 | 2020-06-25 | Auckland Uniservices Limited | Peptide conjugate CGRP receptor antagonists and methods of preparation and uses thereof |
| US20190374518A1 (en) | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| US20190374520A1 (en) * | 2018-06-08 | 2019-12-12 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| TWI826514B (zh) * | 2018-09-04 | 2023-12-21 | 美商美國禮來大藥廠 | 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥 |
| WO2020150703A1 (en) | 2019-01-20 | 2020-07-23 | Biohaven Pharmaceutical Holding Company Ltd. | Cgrp antagonists for treating migraine breakthrough |
| CA3133912A1 (en) | 2019-04-18 | 2020-10-22 | Allergan Sales, Llc | Cgrp antagonists for the treatment of medication overuse headache, post-traumatic headache, post-concussion syndrome and vertigo |
| US20210121541A1 (en) | 2019-07-05 | 2021-04-29 | Allergan Pharmaceuticals International Limited | CGRP Antagonists and Clostridial Derivatives for the Treatment of Neuropsychiatric and Neurological Disorders |
| AU2020355233A1 (en) | 2019-09-25 | 2022-05-19 | Allergan Pharmaceuticals International Limited | Combination therapy with CGRP antagonists |
| EP4188375A4 (en) | 2020-07-29 | 2024-07-24 | Allergan Pharmaceuticals International Limited | MIGRAINE TREATMENT |
| AU2021409718A1 (en) | 2020-12-22 | 2023-07-13 | Allergan Pharmaceuticals International Limited | Treatment of migraine |
| MX2024003952A (es) | 2021-09-27 | 2024-05-27 | Allergan Pharmaceuticals Int Ltd | Combinación que comprende atogepant para tratar la migraña. |
| AU2023231645A1 (en) | 2022-03-09 | 2024-09-12 | Allergan Pharmaceuticals International Limited | Preventive treatment of migraine |
-
2021
- 2021-07-29 EP EP21850713.5A patent/EP4188375A4/en active Pending
- 2021-07-29 BR BR112023001615A patent/BR112023001615A2/pt unknown
- 2021-07-29 CN CN202180054911.0A patent/CN116390712A/zh active Pending
- 2021-07-29 WO PCT/US2021/043791 patent/WO2022026767A1/en not_active Ceased
- 2021-07-29 AU AU2021319090A patent/AU2021319090A1/en active Pending
- 2021-07-29 JP JP2023504814A patent/JP2023535744A/ja active Pending
- 2021-07-29 CA CA3190176A patent/CA3190176A1/en active Pending
- 2021-07-29 MX MX2023001071A patent/MX2023001071A/es unknown
- 2021-07-29 US US17/389,223 patent/US12090148B2/en active Active
-
2024
- 2024-07-10 US US18/768,496 patent/US20250186422A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250186422A1 (en) | 2025-06-12 |
| CN116390712A (zh) | 2023-07-04 |
| EP4188375A4 (en) | 2024-07-24 |
| BR112023001615A2 (pt) | 2023-04-04 |
| US12090148B2 (en) | 2024-09-17 |
| AU2021319090A1 (en) | 2023-03-02 |
| CA3190176A1 (en) | 2022-02-03 |
| US20220031686A1 (en) | 2022-02-03 |
| EP4188375A1 (en) | 2023-06-07 |
| WO2022026767A1 (en) | 2022-02-03 |
| JP2023535744A (ja) | 2023-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003952A (es) | Combinación que comprende atogepant para tratar la migraña. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| EA202193015A1 (ru) | Ингибиторы cdk | |
| MX2022007915A (es) | Compuestos de benzopirazol y analogos de estos. | |
| MX2020013352A (es) | Tratamiento para migrañas. | |
| PH12021552482A1 (en) | Compounds targeting prmt5 | |
| MX2020006599A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
| PH12021550825A1 (en) | Quinoline derivatives as alpha4beta7 integrin inhibitors | |
| MX2021005075A (es) | Metodos para el tratamiento de cancer de prostata resistente a la castracion y sensible a la castracion. | |
| MX2019009501A (es) | Compuestos de amino piridina utiles como inhibidores de ssao. | |
| MX2021007247A (es) | Derivados de rapamicina. | |
| PH12021550713A1 (en) | Medicament for the treatment of chronic cough | |
| MX2023005806A (es) | Tratamiento de cánceres con mutación en oncogen homologo al virus kirsten de sarcoma de rata (kras). | |
| PH12021552513A1 (en) | Pyrrole compounds | |
| PH12016502246B1 (en) | Carboxamide derivatives | |
| BR112023001615A2 (pt) | Tratamento para enxaqueca | |
| MX2021007258A (es) | Composiciones de esparsentan amorfas. | |
| PH12021550452A1 (en) | Methods of treating mycobacterial infections using tetracycline compounds | |
| MX394860B (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| MX2020002630A (es) | Derivados de imidazo[1,5-a]pirazina como inhibidores de fosfatidilinositol-4,5-bisfosfato 3-quinasadelta. | |
| PH12021552953A1 (en) | Tricyclic compounds | |
| WO2021231931A8 (en) | Methods of treating sars-cov-2 infections | |
| PH12019550154A1 (en) | Azetidine derivative | |
| EP4467138A3 (en) | Therapeutic agents for neurodegenerative diseases | |
| MX2021009717A (es) | Sulfonamidas biciclicas. |